9996 Stock Overview
Engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Peijia Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.86 |
| 52 Week High | HK$7.76 |
| 52 Week Low | HK$2.16 |
| Beta | 0.52 |
| 1 Month Change | 0% |
| 3 Month Change | 30.85% |
| 1 Year Change | -43.07% |
| 3 Year Change | -70.08% |
| 5 Year Change | n/a |
| Change since IPO | -85.04% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By Peijia Medical Limited's (HKG:9996) 26% Share Price Surge
Sep 09
Risks Still Elevated At These Prices As Peijia Medical Limited (HKG:9996) Shares Dive 30%
Jul 17More Unpleasant Surprises Could Be In Store For Peijia Medical Limited's (HKG:9996) Shares After Tumbling 27%
Mar 28More Unpleasant Surprises Could Be In Store For Peijia Medical Limited's (HKG:9996) Shares After Tumbling 29%
Jan 22Estimating The Intrinsic Value Of Peijia Medical Limited (HKG:9996)
Dec 05Does Peijia Medical (HKG:9996) Have A Healthy Balance Sheet?
Oct 22Calculating The Fair Value Of Peijia Medical Limited (HKG:9996)
Aug 04Is Peijia Medical (HKG:9996) A Risky Investment?
May 29Getting In Cheap On Peijia Medical Limited (HKG:9996) Is Unlikely
May 10Are Investors Undervaluing Peijia Medical Limited (HKG:9996) By 40%?
Jan 17Despite Lacking Profits Peijia Medical (HKG:9996) Seems To Be On Top Of Its Debt
Oct 05A Look At The Fair Value Of Peijia Medical Limited (HKG:9996)
Aug 29We're Hopeful That Peijia Medical (HKG:9996) Will Use Its Cash Wisely
Mar 16We Think Peijia Medical (HKG:9996) Can Easily Afford To Drive Business Growth
Nov 26We're Hopeful That Peijia Medical (HKG:9996) Will Use Its Cash Wisely
Jul 30Is Peijia Medical Limited (HKG:9996) Worth HK$28.3 Based On Its Intrinsic Value?
May 05Could The Peijia Medical Limited (HKG:9996) Ownership Structure Tell Us Something Useful?
Mar 03Peijia Medical Limited's (HKG:9996) Intrinsic Value Is Potentially 43% Above Its Share Price
Jan 27
We Think Peijia Medical (HKG:9996) Can Afford To Drive Business Growth
Dec 23Shareholder Returns
| 9996 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | -1.3% | -1.6% | -0.5% |
| 1Y | -43.1% | -27.9% | 19.9% |
Return vs Industry: 9996 underperformed the Hong Kong Medical Equipment industry which returned -27.9% over the past year.
Return vs Market: 9996 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 9996 volatility | |
|---|---|
| 9996 Average Weekly Movement | 8.6% |
| Medical Equipment Industry Average Movement | 9.0% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 9996 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9996's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1,050 | Yi Zhang | www.peijiamedical.com |
Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusMax, an iteration steerable TAVR system; TaurusTrio, a TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymeric leaflet TAVR system; Trilogy, a TAVR System; HighLife, a transseptal mitral value replacement system; Sutra Hemi Valve, a TMV coaptation augmentation system; GeminiOne, a transcatheter edge-to-edge repair system; MonarQ which is transcatheter tricuspid valve replacement systems; TaurusAtlas, a transfemoral balloon catheter; TaurusExplora, a pre-shaped guidewire; and TaurusNavi, an introducer sheath. The company also offers Jasper and Presgo, that are detachable coils; Jasper SS detachable coil; intracranial adjunctive stents; SacSpeed, a balloon dilatation catheter; Tethys AS, an aspiration catheter; Syphonet, a stent retriever; Fastunnel, a balloon microcatheter; Fluxcap, a balloon guiding catheter; NeuroStellar, an intracranial stent; Presgo microcatheter and micro guidewire; Heralder guiding catheter and distal access catheter; Tethys, an intermediate catheter; and Jasper power supply.
Peijia Medical Limited Fundamentals Summary
| 9996 fundamental statistics | |
|---|---|
| Market cap | HK$2.52b |
| Earnings (TTM) | -HK$268.28m |
| Revenue (TTM) | HK$551.47m |
4.6x
P/S Ratio-9.4x
P/E RatioIs 9996 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9996 income statement (TTM) | |
|---|---|
| Revenue | CN¥517.46m |
| Cost of Revenue | CN¥146.18m |
| Gross Profit | CN¥371.28m |
| Other Expenses | CN¥623.02m |
| Earnings | -CN¥251.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 71.75% |
| Net Profit Margin | -48.65% |
| Debt/Equity Ratio | 11.4% |
How did 9996 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 03:56 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Peijia Medical Limited is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sharon Shi | BOCI Research Ltd. |
| Yuan Gao | China International Capital Corporation Limited |
| Bo Yu | China International Capital Corporation Limited |